17.54
前日終値:
$18.01
開ける:
$18.04
24時間の取引高:
1.15M
Relative Volume:
0.58
時価総額:
$6.11B
収益:
$3.05B
当期純損益:
$181.32M
株価収益率:
47.02
EPS:
0.373
ネットキャッシュフロー:
$186.11M
1週間 パフォーマンス:
-2.07%
1か月 パフォーマンス:
-6.50%
6か月 パフォーマンス:
+27.01%
1年 パフォーマンス:
+83.66%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
名前
Amneal Pharmaceuticals Inc
セクター
電話
908-947-3120
住所
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
AMRX
Amneal Pharmaceuticals Inc
|
17.54 | 6.23B | 3.05B | 181.32M | 186.11M | 0.373 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.03 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
HLN
Haleon Plc Adr
|
10.11 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.44 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
ZTS
Zoetis Inc
|
77.34 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
515.46 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-17 | 開始されました | UBS | Buy |
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-06-06 | 開始されました | Goldman | Buy |
| 2025-02-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-09-06 | アップグレード | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | アップグレード | Goldman | Sell → Buy |
| 2020-12-14 | アップグレード | Barclays | Equal Weight → Overweight |
| 2020-12-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-07-27 | 開始されました | Goldman | Sell |
| 2020-05-12 | アップグレード | Guggenheim | Sell → Neutral |
| 2019-12-12 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2019-11-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-21 | アップグレード | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-03-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | ダウングレード | SunTrust | Buy → Hold |
| 2018-08-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 開始されました | Morgan Stanley | Overweight |
| 2018-06-22 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Amneal Pharmaceuticals Inc (AMRX) 最新ニュース
Amneal (AMRX) Results Review: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction: The Share Price Adds 1.87% in the Current UpdateProfit Warning Alert - Vinanet
Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest SessionDiluted EPS Report - vinanet.vn
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm - Business Wire
Zacks.com featured highlights include CareDx, Healthcare Services, Forum Energy Tech, Amneal Pharma and Caterpillar - Yahoo Finance
Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance - Sahm
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After A 3.5x Return? - Yahoo Finance
AMRX Q2 2026 Earnings: Strong EPS Beat Drives 5.1% RallyEarnings Revision Upgrade - vinanet.vn
Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026 - Kalkine Media
A Look at Amneal Pharmaceuticals Inc (AMRX) After 5.1% Gain -- G - GuruFocus
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $882,000.00 in Stock - MarketBeat
Amneal Pharmaceuticals (AMRX) director sells 50,000 shares, gifts 10,000 to charity - Stock Titan
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock - Benzinga
Amneal Pharmaceuticals(AMRX.US) Officer Sells US$3.77 Million in Common Stock - Moomoo
Nikita Shah Sells 146,403 Shares of Amneal Pharmaceuticals (NASDAQ:AMRX) Stock - MarketBeat
Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 6,613 Shares - MarketBeat
Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells 210,000 Shares of Stock - MarketBeat
Amneal Pharmaceuticals Insiders Sold Shares Worth Over $6.3M - TradingView
Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings - Stock Titan
AMRX (AMRX) files notice to sell 50,000 common shares - Stock Titan
What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders - Sahm
Amneal (AMRX) major holder gets 12.8M shares in $375M Kashiv purchase - Stock Titan
Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A - Stock Titan
Amneal Pharmaceuticals (AMRX) investor Chirag Patel details 8.4% stake after Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO gains 6.38M shares in Kashiv acquisition - Stock Titan
Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal - Stock Titan
Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal - Stock Titan
AMRX (AMRX) plans Rule 144 resale of 146,403 equity compensation shares - Stock Titan
Amneal Pharmaceuticals, Inc. SEC Filing (Aug 12, 2026) - Stock Titan
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine? - Yahoo Finance
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? - Yahoo Finance
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Shares Fall 4.3% -- GF Value S - GuruFocus
Charles Schwab Corp (AMRX): holder files Form 144 for 2.92M-share sale - Stock Titan
Amneal closes $1.1B Kashiv Biosciences acquisition - NJBIZ
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Amneal Pharma completes acquisition of Kashiv BioSciences - Pharmabiz.com
California State Teachers Retirement System Purchases 56,588 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals Adds $350 Million Incremental Term Loan to Fund Kashiv Acquisition - TradingView
Amneal completes acquisition of Kashiv BioSciences By Investing.com - Investing.com UK
Amneal acquires Kashiv BioSciences, creating global biosimilars leader - Telangana Today
Amneal completes acquisition of Kashiv BioSciences - Investing.com
Amneal Pharmaceuticals Completes Kashiv BioSciences Acquisition - Moomoo
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader - The Manila Times
Oliver Luxxe Assets LLC Has $1.46 Million Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal's New Global Platform Spans Biosimilar Research to Commercialization - Stock Titan
Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals' (NASDAQ:AMRX) Strong Earnings Are Of Good Quality - webull.com
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) 財務データ
収益
当期純利益
現金流量
EPS
Amneal Pharmaceuticals Inc (AMRX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shah Nikita | Executive Vice President |
Aug 12 '26 |
Sale |
17.51 |
146,403 |
2,563,517 |
253,390 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 12 '26 |
Sale |
17.40 |
210,000 |
3,654,000 |
35,171 |
| Daly Jason B. | EVP, Chief Legal Officer |
Aug 11 '26 |
Sale |
17.70 |
6,613 |
117,050 |
245,171 |
大文字化:
|
ボリューム (24 時間):